Lyrica
Product Images NDC 50436-6523

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 50436-6523). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl504366523)

This appears to be a label of medication named "Lyrica". It consists of 90 capsules with 75 mg strength. The label also contains some identification codes, including NDC code and WEG NOC. However, some text is not clearly visible or understandable.*

FDA Label Image

Cockcroft And Gault Equation (Lyrica 01)

FDA Label Image

Chemical Structure (Lyrica 02)

FDA Label Image

Figure 1 (Lyrica 03)

FDA Label Image

Figure 2 (Lyrica 04)

FDA Label Image

Figure 3 (Lyrica 05)

FDA Label Image

Figure 4 (Lyrica 06)

The text is a table showing the percent of patients who improved for three different treatments: Pregabalin 200mg three times per day, Pregabalin 100mg three times per day, and a placebo treatment. The table also includes some illegible characters and a reference to "Pl S Rindina."*

FDA Label Image

Figure 5 (Lyrica 07)

This text appears to be a table showing the percentage of patients who improved after taking certain medications for pain relief. The table lists two drugs, Pregatalin and Progabalin, with their respective dosages and frequency of use. The third column seems to represent the percentage of improvement in pain from baseline for each medication. However, it is unclear what the measurement scale is for this improvement percentage.*

FDA Label Image

Figure 6 (Lyrica 08)

FDA Label Image

Figure 7 (Lyrica 09)

FDA Label Image

Figure 8 (Lyrica 10)

This text seems to be showing different responder rates for some kind of treatment or drug. The rates are displayed in two columns with percentages ranging from 29.4% to 226%. There is also a mention of a placebo and two different dosage levels (2.5 mg/kg/day and 10 mg/kg/day). However, there is not enough context to determine the exact nature of the treatment or drug being evaluated.*

FDA Label Image

Figure 9 (Lyrica 11)

This appears to be a medical document discussing the efficacy of Pregabalin at different doses for patient improvement. The only readable information is that 100% of patients improved. The rest of the text is either non-sensical or contains garbled characters.*

FDA Label Image

Figure 10 (Lyrica 12)

FDA Label Image

Figure 11 (Lyrica 13)

This appears to be a chart or table showing the percentage of subjects who improved after taking Pregabalin, with data points at 50%, 90%, and 100% improvement from a baseline to week 12.*

FDA Label Image

Logo (Lyrica 14)

FDA Label Image

Lyrica 14a

The text provides information about the distribution of products by Parke-Davis, which is a division of Pfizer Inc located in NY, NY 10017.*

FDA Label Image

Lyrica 14b

This is a description of a company that distributes products under the name Parke-Davis, which is a division of Pfizer Inc. The location of Pfizer Inc is in New York, zip code 10017.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.